In addition, NK1R agonists, including SP and hemokinin-1 (HK-1), promote GBM cell proliferation and migration, whereas NK1R antagonists, such as aprepitant, effectively inhibit GBM cell growth in vitro and in vivo [42,43]. This evidence concerns the gene TACR1 and glioblastoma.